The Center for Innovation & Value Research submitted comments on the draft guidance on the Medicare Drug Price Negotiation Program published on May 12, 2025, urging CMS to adopt the following recommendations, making DPNP more scientifically rigorous, transparent and patient-centered:
- Publish explanations of MFP determinations that are comprehensive, consistent, and detailed.
- Strengthen and expand engagement opportunities for patients and family members.
- Measure and evaluate downstream impacts on patient outcomes and access.
Read the full comments here.